Study M028
Study name | Kaddurah-Daouk R 2013 |
Title | Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo |
Overall design | The aim of this study was to characterize early biochemical changes associated with sertraline and placebo administration and changes associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received sertraline (sertraline group, n = 43) or placebo (placebo group, n = 46) in a double-blind 4-week trial; baseline, 1 week, and 4 weeks serum samples were profiled using a gas chromatography time of flight mass spectrometry metabolomics platform. Metabolomic changes after 4 weeks of treatment in both groups were identified. |
Study Type | Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 22 |
Sample size | 89 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; GC-MS: Agilent 6890 gas chromatograph (Santa Clara, CA, USA) interfaced to a Leco Pegasus IV time of flight mass (TOF) spectrometer; |
PMID | |
DOI | |
Citation | Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl Psychiatry 2013;3:e223. |
Metabolite | Linoleic acid; Glycerol; |
